{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:08:32Z","timestamp":1767830912319,"version":"3.49.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion Open Funding Project","award":["NCRCOP2023007"],"award-info":[{"award-number":["NCRCOP2023007"]}]},{"name":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine TuoXin Project","award":["2023008"],"award-info":[{"award-number":["2023008"]}]},{"name":"Special Fund for Clinical Research of Wu Jieping Medical Foundation","award":["320.6750.2023-10-5"],"award-info":[{"award-number":["320.6750.2023-10-5"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11864-025-01353-1","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:30:13Z","timestamp":1757997013000},"page":"866-890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Perioperative Immune Checkpoint Inhibitors for the Treatment of Locally Advanced Gastric and Gastroesophageal Junction Cancer: Current Status and Future Prospects"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4622-9624","authenticated-orcid":false,"given":"Siyuan","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honggen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanming","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"issue":"3","key":"1353_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"10060","key":"1353_CR2","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/S0140-6736(16)30354-3","volume":"388","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(16)30354-3.","journal-title":"Lancet"},{"issue":"10","key":"1353_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"issue":"1","key":"1353_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","unstructured":"Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1\u201325. https:\/\/doi.org\/10.1007\/s10120-022-01331-8.","journal-title":"Gastric Cancer"},{"key":"1353_CR5","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","volume":"27","author":"EC Smyth","year":"2016","unstructured":"Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2016;27:v38\u201349. https:\/\/doi.org\/10.1093\/annonc\/mdw350.","journal-title":"Ann Oncol"},{"key":"1353_CR6","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines for Patients: Stomach Cancer. In: ; 2023. Accessed November 14, 2024. https:\/\/www.nccn.org\/patientresources\/patient-resources\/guidelines-for-patients\/guidelines-for-patients-details?patientGuidelineId=39"},{"issue":"26","key":"1353_CR7","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, Yook JH, Park YK, et al. Prodigy: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39(26):2903\u201313. https:\/\/doi.org\/10.1200\/JCO.20.02914.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1353_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"F Wang","year":"2024","unstructured":"Wang F, Zhang X, Tang L, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 2024;44(1):127\u201372. https:\/\/doi.org\/10.1002\/cac2.12516.","journal-title":"Cancer Commun"},{"issue":"2","key":"1353_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392. https:\/\/doi.org\/10.6004\/jnccn.2022.0008.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"1353_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.soc.2016.10.009","volume":"26","author":"GY Ku","year":"2017","unstructured":"Ku GY. Controversies and consensus in preoperative therapy of esophageal and gastroesophageal junction cancers. Surg Oncol Clin N Am. 2017;26(2):241\u201356. https:\/\/doi.org\/10.1016\/j.soc.2016.10.009.","journal-title":"Surg Oncol Clin N Am"},{"issue":"13","key":"1353_CR11","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715\u201321. https:\/\/doi.org\/10.1200\/JCO.2010.33.0597.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1353_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa055531.","journal-title":"N Engl J Med"},{"issue":"10184","key":"1353_CR13","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"issue":"18","key":"1353_CR14","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810\u201320. https:\/\/doi.org\/10.1056\/NEJMoa072252.","journal-title":"N Engl J Med"},{"issue":"9813","key":"1353_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(11)61873-4.","journal-title":"Lancet"},{"issue":"8","key":"1353_CR16","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(21)00297-7.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1353_CR17","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1097\/JS9.0000000000000692","volume":"109","author":"Y Tian","year":"2023","unstructured":"Tian Y, Yang P, Guo H, et al. Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial. Int J Surg. 2023;109(12):4000\u20138. https:\/\/doi.org\/10.1097\/JS9.0000000000000692.","journal-title":"Int J Surg"},{"issue":"7903","key":"1353_CR18","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942\u20138. https:\/\/doi.org\/10.1038\/s41586-022-04508-4.","journal-title":"Nature"},{"issue":"11","key":"1353_CR19","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6.","journal-title":"Lancet Oncol"},{"issue":"10294","key":"1353_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"21","key":"1353_CR21","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064\u201374. https:\/\/doi.org\/10.1001\/jama.2023.19918.","journal-title":"JAMA"},{"key":"1353_CR22","doi-asserted-by":"publisher","first-page":"S1320","DOI":"10.1016\/j.annonc.2023.10.081","volume":"34","author":"RH Xu","year":"2023","unstructured":"Xu RH, Oh DY, Kato K, et al. LBA80 tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC): final analysis results of the RATIONALE-305 study. Ann Oncol. 2023;34:S1320\u20131. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.081.","journal-title":"Ann Oncol"},{"issue":"2","key":"1353_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(23)00541-7.","journal-title":"Lancet Oncol"},{"key":"1353_CR24","doi-asserted-by":"publisher","first-page":"S1315","DOI":"10.1016\/j.annonc.2023.10.074","volume":"34","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al. LBA73 pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): interim results of the global, phase III MATTERHORN study. Ann Oncol. 2023;34:S1315\u20136. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.074.","journal-title":"Ann Oncol"},{"issue":"1","key":"1353_CR25","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1038\/s41467-023-40480-x","volume":"14","author":"J Wei","year":"2023","unstructured":"Wei J, Lu X, Liu Q, et al. Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial. Nat Commun. 2023;14(1):4904. https:\/\/doi.org\/10.1038\/s41467-023-40480-x.","journal-title":"Nat Commun"},{"issue":"4_suppl","key":"1353_CR26","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1200\/JCO.2023.41.4_suppl.364","volume":"41","author":"X Ding","year":"2023","unstructured":"Ding X, Wang X, Li B, et al. PERSIST: a multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric\/gastroesophageal junction cancer (GC\/GEJC). J Clin Oncol. 2023;41(4_suppl):364\u2013364. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.364.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1353_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41591-023-02758-x","volume":"30","author":"YL Verschoor","year":"2024","unstructured":"Verschoor YL, van de Haar J, van den Berg JG, et al. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial. Nat Med. 2024;30(2):519\u201330. https:\/\/doi.org\/10.1038\/s41591-023-02758-x.","journal-title":"Nat Med"},{"key":"1353_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100189","author":"L Chen","year":"2022","unstructured":"Chen L, Ye Z, Liu G, et al. 85P tislelizumab combined with apatinib and oxaliplatin plus S1 as neoadjuvant therapy for Borrmann IV large Borrmann III type and bulky N positive advanced gastric cancer: a single-arm multicenter trial (TAOS-3B-trial). Immuno-Oncology and Technology. 2022. https:\/\/doi.org\/10.1016\/j.iotech.2022.100189.","journal-title":"Immuno-Oncology and Technology"},{"issue":"8","key":"1353_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"YK Kang","year":"2024","unstructured":"Kang YK, Terashima M, Kim YW, et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. The Lancet Gastroenterology & Hepatology. 2024;9(8):705\u201317. https:\/\/doi.org\/10.1016\/S2468-1253(24)00156-0.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"8","key":"1353_CR30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321. https:\/\/doi.org\/10.1038\/s41423-020-0488-6.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"1353_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01190-w","volume":"7","author":"ZN Lei","year":"2022","unstructured":"Lei ZN, Teng QX, Tian Q, et al. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther. 2022;7(1):358. https:\/\/doi.org\/10.1038\/s41392-022-01190-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"1353_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","volume":"44","author":"GR Khosravi","year":"2024","unstructured":"Khosravi GR, Mostafavi S, Bastan S, Ebrahimi N, Gharibvand RS, Eskandari N. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. 2024;44(5):521\u201353. https:\/\/doi.org\/10.1002\/cac2.12539.","journal-title":"Cancer Commun"},{"issue":"4","key":"1353_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1353_CR34","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/jem.20112741","volume":"209","author":"T Yokosuka","year":"2012","unstructured":"Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201\u201317. https:\/\/doi.org\/10.1084\/jem.20112741.","journal-title":"J Exp Med"},{"issue":"18","key":"1353_CR35","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1073\/pnas.1718217115","volume":"115","author":"E Ahn","year":"2018","unstructured":"Ahn E, Araki K, Hashimoto M, et al. Role of PD-1 during effector CD8 T cell differentiation. Proc Natl Acad Sci U S A. 2018;115(18):4749\u201354. https:\/\/doi.org\/10.1073\/pnas.1718217115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1353_CR36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","volume":"6","author":"J Duan","year":"2020","unstructured":"Duan J, Cui L, Zhao X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 2020;6(3):375\u201384. https:\/\/doi.org\/10.1001\/jamaoncol.2019.5367.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1353_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000400","volume":"8","author":"T Kurino","year":"2020","unstructured":"Kurino T, Matsuda R, Terui A, et al. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1\/PD-L1 blockade-sensitive mouse models. J Immunother Cancer. 2020;8(1):e000400. https:\/\/doi.org\/10.1136\/jitc-2019-000400.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1353_CR38","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","volume":"23","author":"JH Yearley","year":"2017","unstructured":"Yearley JH, Gibson C, Yu N, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23(12):3158\u201367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1761.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1353_CR39","doi-asserted-by":"publisher","first-page":"7746","DOI":"10.4049\/jimmunol.175.11.7746","volume":"175","author":"AV Maker","year":"2005","unstructured":"Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol. 2005;175(11):7746\u201354. https:\/\/doi.org\/10.4049\/jimmunol.175.11.7746.","journal-title":"J Immunol"},{"issue":"8","key":"1353_CR40","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1084\/jem.20082492","volume":"206","author":"KS Peggs","year":"2009","unstructured":"Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717\u201325. https:\/\/doi.org\/10.1084\/jem.20082492.","journal-title":"J Exp Med"},{"issue":"19","key":"1353_CR41","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1158\/1078-0432.CCR-18-2641","volume":"25","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL. The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clin Cancer Res. 2019;25(19):5743\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2641.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1353_CR42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","volume":"26","author":"JM Versluis","year":"2020","unstructured":"Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med. 2020;26(4):475\u201384. https:\/\/doi.org\/10.1038\/s41591-020-0829-0.","journal-title":"Nat Med"},{"issue":"6477","key":"1353_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182","volume":"367","author":"SL Topalian","year":"2020","unstructured":"Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477):eaax0182. https:\/\/doi.org\/10.1126\/science.aax0182.","journal-title":"Science"},{"issue":"6280","key":"1353_CR44","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJS, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463\u20139. https:\/\/doi.org\/10.1126\/science.aaf1490.","journal-title":"Science"},{"issue":"12","key":"1353_CR45","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu J, Blake SJ, Yong MCR, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382\u201399. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0577.","journal-title":"Cancer Discov"},{"issue":"1","key":"1353_CR46","doi-asserted-by":"publisher","first-page":"7078","DOI":"10.1038\/s41598-020-63796-w","volume":"10","author":"A Mart\u00edn-Ruiz","year":"2020","unstructured":"Mart\u00edn-Ruiz A, Fiuza-Luces C, Mart\u00ednez-Mart\u00ednez E, et al. Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model. Sci Rep. 2020;10(1):7078. https:\/\/doi.org\/10.1038\/s41598-020-63796-w.","journal-title":"Sci Rep"},{"issue":"5","key":"1353_CR47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41571-019-0319-9","volume":"17","author":"P Matzner","year":"2020","unstructured":"Matzner P, Sandbank E, Neeman E, Zmora O, Gottumukkala V, Ben-Eliyahu S. Harnessing cancer immunotherapy during the unexploited immediate perioperative period. Nat Rev Clin Oncol. 2020;17(5):313\u201326. https:\/\/doi.org\/10.1038\/s41571-019-0319-9.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1353_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0398-7","volume":"6","author":"O Bakos","year":"2018","unstructured":"Bakos O, Lawson C, Rouleau S, Tai LH. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018;6(1):86. https:\/\/doi.org\/10.1186\/s40425-018-0398-7.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1353_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012.","journal-title":"Immunity"},{"issue":"1","key":"1353_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14(1):156. https:\/\/doi.org\/10.1186\/s13045-021-01164-5.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1353_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;24(6):399\u2013416. https:\/\/doi.org\/10.1038\/s41577-023-00973-8.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"1353_CR52","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725\u201341. https:\/\/doi.org\/10.1038\/s41571-020-0413-z.","journal-title":"Nat Rev Clin Oncol"},{"issue":"16_suppl","key":"1353_CR53","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2022.40.16_suppl.4003","volume":"40","author":"SE Al-Batran","year":"2022","unstructured":"Al-Batran SE, Lorenzen S, Thuss-Patience PC, et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. J Clin Oncol. 2022;40(16_suppl):4003\u20134003. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4003.","journal-title":"J Clin Oncol"},{"key":"1353_CR54","doi-asserted-by":"publisher","first-page":"S856","DOI":"10.1016\/j.annonc.2023.09.1433","volume":"34","author":"MD Santos","year":"2023","unstructured":"Santos MD, Lequesne J, Piessen G, et al. 1520P Perioperative treatment in resectable gastric cancer with spartalizumab combined with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): The GASPAR phase II trial. Ann Oncol. 2023;34:S856. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1433.","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"1353_CR55","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1200\/JCO.2022.40.16_suppl.4059","volume":"40","author":"YL Verschoor","year":"2022","unstructured":"Verschoor YL, Kodach L, van den Berg J, et al. Neoadjuvant atezolizumab plus docetaxel\/oxaliplatin\/capecitabine in non-metastatic gastric and gastroesophageal junction adenocarcinoma: the PANDA trial. J Clin Oncol. 2022;40(16_suppl):4059\u20134059. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4059.","journal-title":"J Clin Oncol"},{"key":"1353_CR56","doi-asserted-by":"publisher","first-page":"S1302","DOI":"10.1016\/j.annonc.2020.10.181","volume":"31","author":"N Li","year":"2020","unstructured":"Li N, Li Z, Fu Q, et al. 160P phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma. Ann Oncol. 2020;31:S1302. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.181.","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"1353_CR57","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1200\/JCO.2024.42.16_suppl.4083","volume":"42","author":"RC Nie","year":"2024","unstructured":"Nie RC, Ding Y, Yuan SQ, et al. Perioperative PD-1 antibody tislelizumab plus chemotherapy for locally advanced gastro-oesophageal junction cancer: a prospective, nonrandomized, open-label, phase II trial. J Clin Oncol. 2024;42(16_suppl):4083\u20134083. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4083.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"1353_CR58","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1200\/JCO.2021.39.15_suppl.4036","volume":"39","author":"Y Liu","year":"2021","unstructured":"Liu Y, Han G, Li H, et al. Camrelizumab combined with FLOFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: updated results of efficacy and safety. J Clin Oncol. 2021;39(15_suppl):4036\u20134036. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4036.","journal-title":"J Clin Oncol"},{"issue":"3_suppl","key":"1353_CR59","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1200\/JCO.2021.39.3_suppl.211","volume":"39","author":"H Jiang","year":"2021","unstructured":"Jiang H, Yu X, Kong M, et al. Sintilimab plus oxaliplatin\/capecitabine (CapeOx) as neoadjuvant therapy in patients with locally advanced, resectable gastric (G)\/esophagogastric junction (GEJ) adenocarcinoma. J Clin Oncol. 2021;39(3_suppl):211\u2013211. https:\/\/doi.org\/10.1200\/JCO.2021.39.3_suppl.211.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1353_CR60","doi-asserted-by":"publisher","first-page":"e16128","DOI":"10.1200\/JCO.2024.42.16_suppl.e16128","volume":"42","author":"H Li","year":"2024","unstructured":"Li H, Ge S, Zang F, et al. Updated results of perioperative PD-1 antibody toripalimab plus FLOT chemotherapy for locally advanced resectable gastric or gastro-esophageal junction adenocarcinoma: a one-arm open-table phase II trial. J Clin Oncol. 2024;42(16_suppl):e16128\u2013e16128. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e16128.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1353_CR61","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1200\/JCO.2022.40.16_suppl.4041","volume":"40","author":"J Tang","year":"2022","unstructured":"Tang J, Huang J, Zhang B, et al. Perioperative chemotherapy with LP002, an anti-PD-L1 antibody, in patients with resectable gastric and gastroesophageal junction cancer: a prospective, open-label, phase Ib trial. J Clin Oncol. 2022;40(16_suppl):4041\u20134041. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4041.","journal-title":"J Clin Oncol"},{"key":"1353_CR62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.300","author":"K Tao","year":"2022","unstructured":"Tao K, Yin Y, Lin Y, et al. Neoadjuvant PD-1 inhibitor tislelizumab combined with s-1 plus oxaliplatin in patients with local advanced gastric cancer or gastroesophageal junction adenocarcinoma: interim results of a single-arm, phase II trial. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.300.","journal-title":"J Clin Oncol"},{"key":"1353_CR63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4074","author":"X Cheng","year":"2024","unstructured":"Cheng X, Xu Z, Zhang Y, et al. Preoperative nivolumab plus SOX in patients with locally advanced gastric or gastro-esophageal junction cancer: a phase 2, single-arm trial. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4074.","journal-title":"J Clin Oncol"},{"key":"1353_CR64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503701","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2503701.","journal-title":"N Engl J Med"},{"key":"1353_CR65","doi-asserted-by":"publisher","unstructured":"Al-Batran SE, Wainberg ZA, Muro K, et al. Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric\/gastroesophageal junction cancer (GC\/GEJC). J Clin Oncol. Published online June 10, 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA5.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5"},{"key":"1353_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.075","volume":"34","author":"K Shitara","year":"2023","unstructured":"Shitara K, Rha SY, Wyrwicz LS, et al. LBA74 pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: the phase III KEYNOTE-585 study. Ann Oncol. 2023;34:S1316. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.075.","journal-title":"Ann Oncol"},{"issue":"3_suppl","key":"1353_CR67","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JCO.2024.42.3_suppl.247","volume":"42","author":"SE Al-Batran","year":"2024","unstructured":"Al-Batran SE, Shitara K, Folprecht G, et al. Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study. J Clin Oncol. 2024;42(3_suppl):247\u2013247. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.247.","journal-title":"J Clin Oncol"},{"key":"1353_CR68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4073","author":"YJ Bang","year":"2024","unstructured":"Bang YJ, Wyrwicz LS, Rha SY, et al. Neoadjuvant\/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric\/gastroesophageal junction (G\/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4073.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1353_CR69","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41591-023-02721-w","volume":"30","author":"SQ Yuan","year":"2024","unstructured":"Yuan SQ, Nie RC, Jin Y, et al. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nat Med. 2024;30(2):552\u20139. https:\/\/doi.org\/10.1038\/s41591-023-02721-w.","journal-title":"Nat Med"},{"issue":"13","key":"1353_CR70","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16(13):e498-509. https:\/\/doi.org\/10.1016\/S1470-2045(15)00007-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1353_CR71","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1038\/s41467-022-34403-5","volume":"13","author":"Z Tang","year":"2022","unstructured":"Tang Z, Wang Y, Liu D, et al. The neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Nat Commun. 2022;13(1):6807. https:\/\/doi.org\/10.1038\/s41467-022-34403-5.","journal-title":"Nat Commun"},{"key":"1353_CR72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4067","author":"CM Pabon","year":"2024","unstructured":"Pabon CM, Xiao L, Badgwell BD, et al. Neoadjuvant dual checkpoint inhibition followed by immune-chemoradiation in patients with resectable gastric adenocarcinoma. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4067.","journal-title":"J Clin Oncol"},{"key":"1353_CR73","doi-asserted-by":"publisher","first-page":"S1104","DOI":"10.1016\/j.annonc.2022.07.1333","volume":"33","author":"R Du","year":"2022","unstructured":"Du R, Ming J, Geng J, et al. 1215P Neoadjuvant concurrent chemoradiotherapy combined with immunotherapy in the treatment of adenocarcinoma of the oesophagogastric junction: A phase II study. Ann Oncol. 2022;33:S1104. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1333.","journal-title":"Ann Oncol"},{"issue":"5","key":"1353_CR74","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340. https:\/\/doi.org\/10.1038\/nrclinonc.2018.29.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1353_CR75","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475\u201385. https:\/\/doi.org\/10.1038\/s12276-020-00500-y.","journal-title":"Exp Mol Med"},{"issue":"5","key":"1353_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112437","volume":"42","author":"Q Luo","year":"2023","unstructured":"Luo Q, Dong Z, Xie W, et al. Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy. Cell Rep. 2023;42(5):112437. https:\/\/doi.org\/10.1016\/j.celrep.2023.112437.","journal-title":"Cell Rep"},{"key":"1353_CR77","doi-asserted-by":"publisher","first-page":"S852","DOI":"10.1016\/j.annonc.2023.09.1425","volume":"34","author":"C Li","year":"2023","unstructured":"Li C, Zheng Y, Shi Z, et al. 1512MO Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV). Ann Oncol. 2023;34:S852. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1425.","journal-title":"Ann Oncol"},{"key":"1353_CR78","doi-asserted-by":"publisher","first-page":"S902","DOI":"10.1016\/j.annonc.2024.08.1520","volume":"35","author":"A Kawazoe","year":"2024","unstructured":"Kawazoe A, Koyama S, Nakayama I, et al. 1454P an open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001). Ann Oncol. 2024;35:S902\u20133. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1520.","journal-title":"Ann Oncol"},{"key":"1353_CR79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4061","author":"S Li","year":"2021","unstructured":"Li S, Yu W, Xie F, et al. A prospective, phase II, single-arm study of neoadjuvant\/conversion therapy with camrelizumab, apatinib, S-1 \u00b1 oxaliplatin for locally advanced cT4a\/bN+ gastric cancer. J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4061.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1353_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35431-x","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, Yu W, Xie F, et al. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023;14(1):8. https:\/\/doi.org\/10.1038\/s41467-022-35431-x.","journal-title":"Nat Commun"},{"issue":"16_suppl","key":"1353_CR81","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1200\/JCO.2023.41.16_suppl.4000","volume":"41","author":"M Terashima","year":"2023","unstructured":"Terashima M, Kang YK, Kim YW, et al. Attraction-5: a phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G\/GEJ) cancer. J Clin Oncol. 2023;41(16_suppl):4000\u20134000. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.4000.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1353_CR82","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.annonc.2024.10.829","volume":"36","author":"F Lordick","year":"2025","unstructured":"Lordick F, Mauer ME, Stocker G, et al. Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and\/or R1): European organisation of research and treatment of cancer (EORTC) 1707 vestige study. Ann Oncol. 2025;36(2):197\u2013207. https:\/\/doi.org\/10.1016\/j.annonc.2024.10.829.","journal-title":"Ann Oncol"},{"key":"1353_CR83","unstructured":"Shanghai Junshi Bioscience Co., Ltd. A Multicenter, Randomized, Double-Blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Postoperative Adjuvant Chemotherapy Versus Placebo Combined With Postoperative Adjuvant Chemotherapy in Patients With Gastric or Esophagogastric Junction Adenocarcinoma After Radical Gastrectomy. ClinicalTrials.gov. January 13, 2025. Accessed February 15, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05180734"},{"issue":"10418","key":"1353_CR84","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197\u2013208. https:\/\/doi.org\/10.1016\/S0140-6736(23)02033-0.","journal-title":"Lancet"},{"issue":"7890","key":"1353_CR85","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Ya\u00f1ez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727\u201330. https:\/\/doi.org\/10.1038\/s41586-021-04161-3.","journal-title":"Nature"},{"key":"1353_CR86","unstructured":"U.S. Food & Drug Administration. FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma. FDA. December 5, 2021. Accessed November 16, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-combination-trastuzumab-fluoropyrimidine"},{"key":"1353_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1451","volume":"34","author":"F Wang","year":"2023","unstructured":"Wang F, Zhao C, Xia J, et al. 1539p efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric\/gastroesophageal junction cancer (GC\/EGJC): preliminary results of a phase II, single-arm trial. Ann Oncol. 2023;34:S865. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1451.","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"1353_CR88","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1200\/JCO.2022.40.4_suppl.296","volume":"40","author":"N Li","year":"2022","unstructured":"Li N, Li Z, Fu Q, et al. Phase II study of SHR1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol. 2022;40(4_suppl):296\u2013296. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.296.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1353_CR89","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1245\/s10434-021-11050-6","volume":"29","author":"RC Nie","year":"2022","unstructured":"Nie RC, Chen GM, Yuan SQ, et al. Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: systematic review and meta-analysis. Ann Surg Oncol. 2022;29(4):2324\u201331. https:\/\/doi.org\/10.1245\/s10434-021-11050-6.","journal-title":"Ann Surg Oncol"},{"issue":"35","key":"1353_CR90","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","volume":"37","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37(35):3392\u2013400. https:\/\/doi.org\/10.1200\/JCO.19.01124.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1353_CR91","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jso.23618","volume":"110","author":"YY Choi","year":"2014","unstructured":"Choi YY, Bae JM, An JY, et al. Is microsatellite instability a prognostic marker in gastric cancer?: A systematic review with meta-analysis. J Surg Oncol. 2014;110(2):129\u201335. https:\/\/doi.org\/10.1002\/jso.23618.","journal-title":"J Surg Oncol"},{"issue":"9","key":"1353_CR92","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3(9):1197\u2013203. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6762.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1353_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101691","volume":"45","author":"ML Tran- Minh","year":"2021","unstructured":"Tran-Minh ML, Lehmann-Che J, Lambert J, et al. Prevalence and prognosis of microsatellite instability in oesogastric adenocarcinoma, NORDICAP 16\u201301. Clin Res Hepatol Gastroenterol. 2021;45(4):101691. https:\/\/doi.org\/10.1016\/j.clinre.2021.101691.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1353_CR94","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017. https:\/\/doi.org\/10.1126\/science.aan6733.","journal-title":"Science"},{"issue":"2","key":"1353_CR95","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41(2):255\u201365. https:\/\/doi.org\/10.1200\/JCO.22.00686.","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"1353_CR96","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1200\/JCO.2023.41.4_suppl.358","volume":"41","author":"F Pietrantonio","year":"2023","unstructured":"Pietrantonio F, Raimondi A, Lonardi S, et al. INFINITY: a multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC\/GEJAC). J Clin Oncol. 2023;41(4_suppl):358\u2013358. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.358.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1353_CR97","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2023.41.16_suppl.2591","volume":"41","author":"C De La Fouchardiere","year":"2023","unstructured":"De La Fouchardiere C, Zaanan A, Cohen R, et al. Immunotherapy for localized dMMR\/MSI tumors: first interim analysis of the IMHOTEP trial. J Clin Oncol. 2023;41(16_suppl):2591\u20132591. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.2591.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1353_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003635","volume":"10","author":"H Jiang","year":"2022","unstructured":"Jiang H, Yu X, Li N, et al. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. J Immunother Cancer. 2022;10(3):e003635. https:\/\/doi.org\/10.1136\/jitc-2021-003635.","journal-title":"J Immunother Cancer"},{"key":"1353_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1538","volume":"32","author":"SE Al-Batran","year":"2021","unstructured":"Al-Batran SE, Lorenzen S, Homann N, et al. 1429P pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: results from the DANTE trial of the German Gastric Group at the AIO and SAKK. Ann Oncol. 2021;32:S1069. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1538.","journal-title":"Ann Oncol"},{"issue":"1","key":"1353_CR100","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol Mech Dis. 2021;16(1):223\u201349. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"1353_CR101","unstructured":"ClinicalTrials.gov. A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant\/Adjuvant Treatment of Gastric Cancer. June 6, 2022. Accessed December 14, 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT04139135?term=NCT04139135&rank=1"},{"issue":"4","key":"1353_CR102","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.24.00795","volume":"43","author":"C Li","year":"2024","unstructured":"Li C, Tian Y, Zheng Y, et al. Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV\/CAP 05). J Clin Oncol. 2024;43(4):464\u201374. https:\/\/doi.org\/10.1200\/JCO.24.00795.","journal-title":"J Clin Oncol"},{"key":"1353_CR103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.349","author":"H Liu","year":"2024","unstructured":"Liu H, Hu Y, Yu J, et al. Neoadjuvant toripalimab plus CapeOX in patients with localized dMMR\/MSI-H gastric or esophagogastric junction adenocarcinoma (GC\/EGJC): results from the cohort C of phase II NICE trial. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.349.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1353_CR104","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s10120-021-01195-4","volume":"24","author":"B Schoemig-Markiefka","year":"2021","unstructured":"Schoemig-Markiefka B, Eschbach J, Scheel AH, et al. Optimized PD-L1 scoring of gastric cancer. Gastric Cancer. 2021;24(5):1115\u201322. https:\/\/doi.org\/10.1007\/s10120-021-01195-4.","journal-title":"Gastric Cancer"},{"issue":"12","key":"1353_CR105","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/cncr.35307","volume":"130","author":"L Kolla","year":"2024","unstructured":"Kolla L, Parikh RB. Uses and limitations of artificial intelligence for oncology. Cancer. 2024;130(12):2101\u20137. https:\/\/doi.org\/10.1002\/cncr.35307.","journal-title":"Cancer"},{"issue":"3_suppl","key":"1353_CR106","doi-asserted-by":"publisher","first-page":"LBA246","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA246","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. J Clin Oncol. 2024;42(3_suppl):LBA246\u2013LBA246. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.LBA246.","journal-title":"J Clin Oncol"},{"key":"1353_CR107","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1016\/j.annonc.2024.06.007","volume":"35","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, et al. LBA3 final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer. Ann Oncol. 2024;35:S213. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.007.","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"1353_CR108","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1200\/JCO.2023.41.16_suppl.4001","volume":"41","author":"S Yuan","year":"2023","unstructured":"Yuan S, Nie RC, Jin Y, et al. Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: results from a prospective, randomized, open-label, phase II trial. J Clin Oncol. 2023;41(16_suppl):4001\u20134001. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.4001.","journal-title":"J Clin Oncol"},{"key":"1353_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.959295","author":"Y Yin","year":"2022","unstructured":"Yin Y, Lin Y, Yang M, et al. Neoadjuvant tislelizumab and tegafur\/gimeracil\/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: early results of a phase 2, single-arm trial. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.959295.","journal-title":"Front Oncol"},{"issue":"6","key":"1353_CR110","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40259-016-0204-3","volume":"30","author":"D Day","year":"2016","unstructured":"Day D, Hansen AR. Immune-related adverse events associated with immune checkpoint inhibitors. BioDrugs. 2016;30(6):571\u201384. https:\/\/doi.org\/10.1007\/s40259-016-0204-3.","journal-title":"BioDrugs"},{"issue":"4","key":"1353_CR111","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367. https:\/\/doi.org\/10.1038\/s41571-022-00600-w.","journal-title":"Nat Rev Clin Oncol"},{"issue":"16_suppl","key":"1353_CR112","doi-asserted-by":"publisher","first-page":"e16084","DOI":"10.1200\/JCO.2023.41.16_suppl.e16084","volume":"41","author":"C Zhao","year":"2023","unstructured":"Zhao C, Meng X, Shan Z, et al. Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric\/gastroesophageal junction cancer (GC\/EGJC): preliminary results of a phase 2, single-arm trial. J Clin Oncol. 2023;41(16_suppl):e16084\u2013e16084. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16084.","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"1353_CR113","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1200\/JCO.2022.40.4_suppl.294","volume":"40","author":"X Ding","year":"2022","unstructured":"Ding X, Li B, Xue Q, et al. Perioperative sintilimab combination with SOX for resectable locally advanced gastric\/gastroesophageal junction cancer(GC\/GEJC): initial findings of a single-arm phase II trial. J Clin Oncol. 2022;40(4_suppl):294\u2013294. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.294.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"1353_CR114","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1200\/JCO.2021.39.15_suppl.4046","volume":"39","author":"T Alcindor","year":"2021","unstructured":"Alcindor T, Opu T, Elkrief A, et al. Phase II trial of perioperative chemotherapy + avelumab in locally advanced gastroesophageal adenocarcinoma: preliminary results. J Clin Oncol. 2021;39(15_suppl):4046\u20134046. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4046.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1353_CR115","doi-asserted-by":"publisher","first-page":"e16044","DOI":"10.1200\/JCO.2022.40.16_suppl.e16044","volume":"40","author":"Z Liu","year":"2022","unstructured":"Liu Z, Liu N, Zhou Y, et al. Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy: data update. J Clin Oncol. 2022;40(16_suppl):e16044\u2013e16044. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e16044.","journal-title":"J Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01353-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01353-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01353-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:35:41Z","timestamp":1759995341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01353-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":115,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1353"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01353-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"6 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}